Immatics N.V. Ordinary Shares
IMTXImmatics N.V. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer. The company specializes in T-cell receptor (TCR) therapies, aiming to harness the immune system to target and destroy tumor cells. Based in Germany, Immatics advances personalized medicine approaches through its proprietary technological platform to identify and develop targeted treatments for various cancers.
Company News
Immatics announced extended Phase 1b data for anzu-cel (IMA203), a PRAME-directed TCR T-cell therapy, showing 56% confirmed objective response rate, 14.6 months median duration of response, and 16.2 months median overall survival in metastatic melanoma patients. The therapy demonstrated rapid, deep and durable anti-tumor activity with a manageabl...
Over 15 pharmaceutical companies are actively developing more than 20 pipeline drugs for synovial sarcoma treatment, with promising therapies in various clinical trial stages. Key players including Takara Bio, Immatics, Moderna, Adaptimmune, and Zelluna are advancing innovative approaches such as TCR-T therapies and bispecific antibodies to addre...
Immatics announced that a 17-year-old patient with advanced metastatic nephroblastoma achieved deep remission following treatment with a PRAME-directed TCR T-cell therapy. The patient, who had exhausted all available treatment options, experienced marked regression of liver, lung, and brain metastases with ongoing response at 6 months follow-up. ...
Immatics reported promising initial anti-tumor activity for its second-generation PRAME cell therapy IMA203CD8 in a Phase 1a dose escalation trial, showing encouraging clinical responses across multiple cancer types, particularly in ovarian carcinoma.
Immatics N.V. plans to sell 12.5 million ordinary shares at $10.00 per share, expecting to raise $125 million in a public offering managed by Jefferies, Leerink Partners, and Cantor.
